Abstract:Mortality associated with liver disease has been observed in patients with short bowel syndrome (SBS); however, its mechanism remains unclear, but bile acid (BA) dysmetabolism has been proposed as a possible cause. The farnesoid X receptor (FXR) is the key regulator of BA synthesis. Here, we showed that, in a rat model of short bowel resection associated with liver disease (SBR-ALD). the BA composition of hepatic tissues reflected a larger proportion of primary and secondary unconjugated BAs, whereas that of the colon contents and serum showed an increased ratio of secondary unconjugated BAs. Both hepatic and intestinal regulation of BA synthesis was characterized by a blunted hepatic FXR activation response. The mRNA expression levels of cholesterol 7a-hydroxylase (CYP7A1), sterol 12a-hydroxylase (CYP8B1), and sterol 27 hydroxylase (CYP27A1), the key enzymes in BA synthesis, were upregulated. After intervention with the FXR agonist GW4064, both the liver histology and serum transaminase activity were improved, which demonstrated the attenuation of SBR-AIL). The BA compositions of hepatic tissue, the colon contents, and serum recovered and were closer to those of the sham group. The expression levels of hepatic FXR increased, and its target genes were activated. Consistent with this, the expression levels of CYP7A1, CYP8B1, and CYP27A1 were downregulated. Ileum tissue FXR and its target genes were slightly elevated. This study showed that the FXR agonist GW4064 could correct BA dysmetabolism to alleviate hepatotoxicity in SBR animals. GW4064 intervention resulted in a decrease in fecal bile excretion and elevated plasma/hepatic conjugated BA levels. GW4064 increased the reabsorption of conjugated BAs by inducing apical sodium-dependent bile salt transporter expression in the ileum. Concomitantly, FXR activation in the presence of GW4064 decreased BA production by repressing the expression of key synthetases, including CYP7A1, CYP8B1, and CYP27A1. These findings provide a clinical research direction for the prevention of liver disease in patients with SBS. NEW & NOTEWORTHY This study assessed the impact of treatment with GW4064, a farnesoid X receptor agonist. on the development of short bowel resection (SBR) associated with liver disease in a rat model of SBR. GW4064 was able to correct bile acid dysmetabolism and alleviate hepatotoxicity in SBR animals.

A rapid administration of GW4064 inhibits the NLRP3 inflammasome activation independent of farnesoid X receptor agonism

FXR Agonist GW4064 Alleviates Endotoxin-Induced Hepatic Inflammation by Repressing Macrophage Activation.

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

NLRP3 Inflammasome Inhibitor INF39 Attenuated NLRP3 Assembly in Macrophages.

Unbinding Pathways of GW4064 from Human Farnesoid X Receptor As Revealed by Molecular Dynamics Simulations.

FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer

A Potential Role of GW4064 to Inhibit Gut Bacterial Overgrowth by Activating FXR in Suppression of Ethanol-Induced Liver Injury

GW4064 inhibits migration and invasion through cathepsin B and MMP2 downregulation in human bladder cancer

Suppression of NF-κB Signaling and NLRP3 Inflammasome Activation in Macrophages is Responsible for the Amelioration of Experimental Murine Colitis by the Natural Compound Fraxinellone

The Angiotensin II Receptor Neprilysin Inhibitor LCZ696 Inhibits the NLRP3 Inflammasome By Reducing Mitochondrial Dysfunction in Macrophages and Alleviates Dextran Sulfate Sodium-induced Colitis in a Mouse Model

Spirodalesol Analog 8A Inhibits NLRP3 Inflammasome Activation and Attenuates Inflammatory Disease by Directly Targeting Adaptor Protein ASC.

Ginsenoside Rg3 suppresses the NLRP3 inflammasome activation through inhibition of its assembly

FXR activation reduces the formation of macrophage foam cells and atherosclerotic plaque, possibly by down regulating hepatic lipase in macrophages

GW4064 Enhances the Chemosensitivity of Colorectal Cancer to Oxaliplatin by Inducing Pyroptosis

FXR agonist GW4064 improves the liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection.

RRx-001 Ameliorates Inflammatory Diseases by Acting As a Potent Covalent NLRP3 Inhibitor

Identification of D359-0396 as a novel inhibitor of the activation of NLRP3 inflammasome

Functional Characterization of an Arylsulfonamide-Based Small-Molecule Inhibitor of the NLRP3 Inflammasome

An RRx-001 Analogue With Potent Anti-NLRP3 Inflammasome Activity but Without High-Energy Nitro Functional Groups

Farnesoid X Receptor Activation Protects Liver from Ischemia/Reperfusion Injury by Up‐Regulating Small Heterodimer Partner in Kupffer Cells

Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors